ArticleFrontiers in neurology2025
Characteristics of dysarthria in patients with spinocerebellar degeneration and multiple system atrophy: a cross-sectional and longitudinal study using the Frenchay Dysarthria Assessment Second Edition (FDA-2).
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to evaluate the dysarthria of patients with spinocerebellar degeneration and multiple system atrophy (SCD/MSA) cross-sectionally and longitudinally using the Frenchay Dysarthria Assessment Second Edition (FDA-2), which provides a comprehensive assessment of dysarthria, and to clarify characteristic patterns and longitudinal changes. Materials and methods: A total of 21 patients with SCD and MSA were included. Patients' dysarthria was assessed using the FDA-2 and the Scale for the Assessment and Rating of Ataxia (SARA) item 4(SARA speech) at intervals of ≥ 12 months. Changes over time were examined with a paired t-test and Wilcoxon's signed-rank test. Multiple regression analysis explored determinants of speech intelligibility, with FDA-2 intelligibility as the dependent variable and respiration, lips, palate, laryngeal, and tongue subscores as predictors. Results: The number of patients according to disease types was SCA2 in 1, SCA3 in 8, SCA31 in 1, MSA-C in 8, and an undetermined disease type in 3. The examination interval was 31.1 ± 15.6 months. FDA-2 scores were lower for repetitive-movement or speech items than for rest items. Lips and palate subscores were relatively higher, whereas laryngeal and tongue subscores were lower. Over time, reflex, lips, laryngeal, tongue, and total scores declined significantly, whereas the palate, respiration, and intelligibility scores remained stable. Multiple regression identified the laryngeal subscores as the only significant predictor of intelligibility (Sβ = 0.77, Conclusion: The FDA-2 revealed a distinct dysarthria profile in SCD/MSA. Longitudinal FDA-2 monitoring may facilitate early detection and targeted intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.